Nephrotoxicity
Q: The drug cisplatin is an alkylating agent commonly used in chemotherapy and is known to cause ototoxicity and nephrotoxicity. True or False?
Did You Know?
Patients with acute leukemia, particularly those undergoing intensive chemotherapy or stem cell transplant, can show significant ABO typing discrepancies over time due to two main mechanisms. First, chemotherapy causes severe immunosuppression, which can lead to a loss of detectable ABO antibodies (hypogammaglobulinemia), making reverse grouping weak or negative. Second, and more profoundly, if the patient receives an allogeneic hematopoietic stem cell transplant (HSCT) from a donor with a different ABO type, they will eventually produce red blood cells of the donor's type. During the transition period (engraftment), the patient will have a mixture of their own native red cells and the donor's red cells, resulting in a mixed field agglutination pattern or even a complete change in their forward ABO type. This state is called graft-derived chimerism and requires special blood banking protocols to ensure safe transfusions.
Social Sharing!
Share your knowledge:
Zambia